Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD204 vs Avastin in metastatic or recurrent non-squamous NSCLC
NCT03390686Phase 3Active, not recruiting
- Sponsor
- Prestige Biopharma Limited
- Start
- Nov 2019
- Primary completion
- Jul 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of HLX04 in non-small cell lung cancer (NSCLC), sponsored by Prestige Biopharma Limited. Started Nov 2019; status: active, not recruiting.
02
Drugs
HLX04
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03390686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03390686.